Fasting C-Peptide - Blood Sample Handling and Time to Lab

Collection

• Draw 7 mL venous blood in a red-top (serum clot) tube or a serum separator tube (SST / gel tube). Some protocols accept EDTA (lavender-top) tubes as well.
• Allow blood to clot at room temperature for no more than 20-30 minutes.

Critical Time Requirement

The Standard Answer (for most exam/clinical contexts):

Blood for fasting C-peptide should be sent to the lab within 30 minutes of collection, transported on ice (chilled).

Why the urgency?

• C-peptide is more stable than insulin (it has minimal hepatic metabolism and a longer half-life of ~30 minutes vs ~5 minutes for insulin), but it can still degrade at room temperature over time.
• EDTA plasma samples are stable at room temperature for up to 24 hours, which is why some labs prefer EDTA tubes if transport is delayed.

Sample stability summary (from lab guidelines):

• Room temperature (unseparated whole blood): Process within 30-60 minutes
• Serum/plasma at 2-8°C (refrigerated): Stable for 24-48 hours
• Frozen at -20°C: Stable for months
• Frozen at -70°C: Long-term archival storage

Indications for CMV IgM Serum Testing

1. Diagnosis of Acute/Primary CMV Infection

• In an immunocompetent adult presenting with a mononucleosis-like syndrome (fever, fatigue, hepatitis, lymphadenopathy) with a negative monospot test - CMV is the key differential alongside EBV.
• CMV IgM positive + IgG seroconversion = strong evidence of primary infection.
• Important caveat: CMV IgM cannot be used alone to confirm primary infection - it can also be positive in reactivation or reinfection. Always pair with IgG avidity testing: low IgG avidity + IgM positive = primary infection within last 2-4 months.

2. Pregnant Women with Suspected CMV Exposure

• CMV is the most common congenital viral infection in humans.
• Any pregnant woman with flu-like illness, transaminitis, or known CMV exposure should have CMV IgM + IgG + IgG avidity tested.
• Primary CMV in pregnancy (especially 1st trimester) carries the highest risk of fetal damage (hearing loss, microcephaly, intracranial calcifications, IUGR, retinitis, thrombocytopenia).
• A positive IgM with low IgG avidity in the 1st trimester should prompt amniocentesis + CMV PCR of amniotic fluid.

3. Suspected Congenital CMV in the Newborn

• Any neonate with: microcephaly, sensorineural hearing loss (failed newborn hearing screen), intracranial calcifications, petechiae/thrombocytopenia, hepatosplenomegaly, or jaundice.
• CMV IgM at birth has sensitivity ~84% and specificity ~99% for congenital CMV infection.
• CMV IgM positive at birth (where the infant cannot have passively transferred IgM from the mother) = strong indicator of intrauterine infection.
• Definitive diagnosis: urine/saliva PCR or rapid viral culture within first 3 weeks of life.

4. Pre-Transplant Screening (Donor and Recipient)

• CMV IgM (along with IgG) is checked in organ transplant donors and recipients to assess serostatus.
• A CMV IgM-positive donor or recipient flags active/recent infection.
• Serodiscordant transplants (donor IgG+/recipient IgG-) are highest risk and require valganciclovir prophylaxis post-transplant.
• Note: Post-transplant monitoring relies primarily on quantitative CMV DNA PCR, not serology.

5. Immunocompromised Patients with Febrile Illness

• HIV/AIDS patients, transplant recipients, or those on immunosuppressants with fever, pneumonitis, colitis, hepatitis, retinitis, or leukopenia.
• Again, CMV DNA PCR is preferred in these patients; serology is less reliable because immunocompromised patients may not mount a normal antibody response.

6. Evaluation of CMV Hepatitis

• CMV can cause mild transaminitis in immunocompetent hosts or acute liver failure in immunosuppressed patients.
• CMV IgM is part of the workup for viral hepatitis of undetermined cause.

Interpretation Summary Table

Key Limitations of CMV IgM

1. Not specific for primary infection - also positive in reactivation and reinfection
2. Persists for up to 6 months making it hard to time the infection
3. False positives are common (other viral infections, rheumatoid factor interference)
4. In immunocompromised hosts, IgM may be falsely negative due to poor antibody response
5. CMV IgM alone is insufficient - always interpret with IgG and IgG avidity

Bottom line for clinical use: CMV IgM is most useful as a screening/initial test for suspected acute CMV, especially in pregnancy and neonates. Confirm with IgG avidity and/or CMV PCR.

CMV IgM Serum - Indication in Fulminant Hepatitis

Why is CMV IgM ordered in Fulminant Hepatitis?

Role of CMV in Fulminant Hepatitis

Where CMV IgM Fits in the ALF Workup

• HAV IgM
• HBsAg, HBcAb IgM, HBV PCR
• HCV PCR
• HEV PCR (if endemic)
• EBV PCR, CMV PCR, HSV PCR, VZV PCR

Note: In current ALF guidelines, CMV PCR is preferred over CMV IgM, because:

• PCR is faster, more sensitive, and reliable even in immunocompromised patients who may not mount an IgM response
• IgM can be falsely positive (rheumatoid factor, other viral infections, persistent IgM from old infection)
• IgM can be falsely negative in immunosuppressed hosts

1. PCR is unavailable or results are pending
2. Patient is immunocompetent (IgM serology is sufficient and cost-effective)
3. As part of a complete "mononucleosis panel" (CMV IgM + EBV screen) in young adults with ALF
4. For risk stratification in transplant evaluation (pre-transplant serostatus of the ALF patient)

Specific Clinical Scenario - When CMV IgM Clinches the Diagnosis

• Acute hepatitis (ALT/AST markedly elevated)
• Negative HAV, HBV, HCV, HEV serology
• Negative autoimmune markers (ANA, ASMA)
• Negative toxicology
• Mononucleosis-like features (fever, lymphadenopathy)

Key Limitations to Keep in Mind

• In immunocompromised ALF: do NOT rely on IgM alone - use CMV DNA PCR quantitative (serology unreliable due to impaired antibody response)
• CMV IgM persists for up to 6 months - a positive result does not always mean the current ALF episode is CMV-related
• Always pair CMV IgM with IgG avidity for timing confirmation

The R Factor (R Value / R Ratio) in Liver Disease

Definition

Formula

• ALT = measured alanine aminotransferase
• ALP = measured alkaline phosphatase
• ULN = upper limit of normal for the respective enzyme
• AST may substitute for ALT when ALT is unavailable

Interpretation (CIOMS/DILI Expert Working Group)

Primary Use: Drug-Induced Liver Injury (DILI)

"The clinical pattern of drug-induced liver injury is defined by the R-value, which is calculated as the ALT:ALP ratio, where each is expressed in terms of the upper limit of normal."

• Isoniazid, macrolides, nitrofurantoin, minocycline, NSAIDs, anti-epileptics, green tea extract, inhaled anesthetics

• Amoxicillin-clavulanate, trimethoprim-sulfamethoxazole, azathioprine, anabolic/androgenic steroids, estrogens

• Drugs that can cause both patterns (e.g., amoxicillin-clavulanate can also cause mixed)

Also Used to Direct Differential Diagnosis in Any Liver Injury

Important Caveats

1. Use the FIRST abnormal set of lab values to calculate R - the ratio shifts over time as disease evolves
2. In patients with pre-existing abnormal LFTs (e.g., cirrhosis), use the baseline values instead of standard ULN
3. R factor alone does not assess severity - always check INR and mental status to rule out ALF
4. The 2011 International DILI Expert Working Group raised the ALT cutoff to ≥5× ULN to exclude self-limited, clinically insignificant hepatocellular events